NCCN Announces Collaboration With Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients With Prostate Cancer

The NCCN Oncology Research Program (ORP) announced a collaboration with Pfizer and Myovant Sciences to fund research projects seeking to improve cardiovascular management of patients with prostate cancer being treated with androgen deprivation therapy (ADT).

“Cardiovascular disease is an important comorbid condition in many patients living with prostate cancer, especially in those receiving ADT,” said Crystal S. Denlinger, MD, Senior Vice President, Chief Scientific Officer, NCCN. “Congratulations to all of these inspiring investigators. We hope their work can advance the management of cardiovascular risk to improve overall health of this patient population.”

The selected research projects are:

- Zhaoping Li, MD, PhD, David Geffen School of Medicine at UCLA
  - Contribution of Race to Nutritional Approach to Lower Cardiovascular Risk Factors in Men Undergoing Androgen Deprivation Therapy

- Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
  - CV CARE: Cardiovascular Care of Androgen Related Effects in Prostate Cancer Patients

- Vivek Narayan, MD, MSCE, University of Pennsylvania, Abramson Cancer Center
  - The Cardiovascular Risk Evaluation in Men With Prostate Cancer (CARE-PC): Pilot Feasibility Study to Assess Patient Awareness and Risk Mitigation

- Camille Ragin, PhD, MPH, and Daniel Geynisman, MD, Fox Chase Cancer Center
  - Investigating the Role of African Genetic Ancestry in Cardiovascular Complications and Cardiotoxicity Among Prostate Cancer Patients Post Treatment With Androgen Deprivation Therapy

- Balaji Tamarappoo, MD, PhD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  - Personalized Medical Treatment of Coronary Atherosclerosis in Prostate Cancer Patients Guided by Plaque Assessment With Quantitative Coronary CT Angiography

Roughly half of patients treated for prostate cancer receive ADT, often for prolonged durations. A majority of patients may have preexisting risk factors for cardiovascular disease, which is the primary cause of noncancer death among patients with prostate cancer. Data also show that roughly a third of patients with uncontrolled risk factors for cardiovascular events are not taking appropriate medications. The goal of this project is to improve the awareness, identification, and implementation of interventions for known modifiable cardiovascular disease risk factors (ie, hypertension, dyslipidemia, diabetes).

Proposals were peer-reviewed by a Scientific Review Committee, which consisted of leading expert clinicians and scientists from NCCN Member Institutions. The selected projects are set to be completed within 3 years. The total amount of grants awarded for this research is approximately $1.5 million.

doi: 10.6004/jnccn.2022.0055